Caxton Associates (New York)’s Myriad Genetics MYGN Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Shares Change %	Capital Flow	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-29,319	Closed	-$533K	–	588
2022 Q2	$533K	Buy	+29,319	New	+$533K	0.05%	239
2020 Q3	–	Sell	-10,933	Closed	-$124K	–	434
2020 Q2	$124K	Buy	+10,933	New	+$124K	0.01%	398